CytoDyn (CYDY) Amortization of Deferred Charges (2013 - 2025)
CytoDyn (CYDY) posted Amortization of Deferred Charges of $325000.0 for Q4 2025, up 450.85% on a QoQ basis from $59000.0 in Q2 2025, and up 187.61% year-over-year from $113000.0 in Q4 2024.
CytoDyn (CYDY) Amortization of Deferred Charges (2013 - 2025) Analysis & Trends
CytoDyn's Amortization of Deferred Charges history runs 13 years deep, the most recent figure standing at $325000.0 for Q4 2025.
- Quarterly Amortization of Deferred Charges rose 187.61% year-over-year to $325000.0 in Q4 2025, while the trailing twelve-month figure through Nov 2025 was $607000.0 (up 37.64% YoY) and the FY2025 annual result came in at $407000.0, down 28.85% from the prior year.
- Amortization of Deferred Charges was $325000.0 for Q4 2025 at CytoDyn, up from $59000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $366000.0 in Q3 2023 and bottomed at $3000.0 in Q4 2023.
- A 5-year average of $83666.7 and a median of $24000.0 in 2021 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2023 — Amortization of Deferred Charges slumped 83.33% — and 2024, when it soared 3666.67%.
- CytoDyn's Amortization of Deferred Charges stood at $23000.0 in 2021, then decreased by 21.74% to $18000.0 in 2022, then slumped by 83.33% to $3000.0 in 2023, then surged by 3666.67% to $113000.0 in 2024, then jumped by 187.61% to $325000.0 in 2025.
- Business Quant data shows CYDY's Amortization of Deferred Charges at $325000.0 in Q4 2025, $59000.0 in Q2 2025, and $110000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - |
| 2 | Nanobiotix | 1,880.51 Bn | 1,880.45 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 467.94 Bn | 463.15 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.63 Bn | 115.38 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.30 Bn | 61.54 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.81 Bn | 62.81 Bn | - |
| 8 | Argenx Se | 55.78 Bn | 50.59 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn |
| 10 | CytoDyn | 261.29 Mn | 261.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2025 | 325,000.00 |
| Nov 30, 2025 | 325,000.00 |
| May 31, 2025 | 59,000.00 |
| May 31, 2025 | 59,000.00 |
| Feb 28, 2025 | 110,000.00 |
| Feb 28, 2025 | 110,000.00 |
| Nov 30, 2024 | 113,000.00 |
| Nov 30, 2024 | 113,000.00 |
| Aug 31, 2024 | 125,000.00 |
| Aug 31, 2024 | 125,000.00 |
| Feb 29, 2024 | 203,000.00 |
| Feb 29, 2024 | 203,000.00 |
| Nov 30, 2023 | 3,000.00 |
| Nov 30, 2023 | 3,000.00 |
| Aug 31, 2023 | 366,000.00 |
| Aug 31, 2023 | 366,000.00 |
| May 31, 2023 | 18,000.00 |
| May 31, 2023 | 18,000.00 |
| Feb 28, 2023 | 17,000.00 |
| Feb 28, 2023 | 17,000.00 |